Evidence map›Paper›PMID 36196472›Full record

ReviewJournal of clinical hypertension (Greenwich, Conn.)2022

Standardized home blood pressure monitoring: Rationale behind the 722 protocol.

Hung-Ju Lin, Heng-Yu Pan, Chen-Huan Chen, Hao-Min Cheng, Yook-Chin Chia, Guru Prasad Sogunuru, Jam Chin Tay, Yuda Turana, Narsingh Verma, Kazuomi Kario and 1 more

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Investigating feature-engineered predictors for systolic blood pressure changes in an mHealth-based disease management program.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  3. Review
  4. Article
  5. Standardized home blood pressure monitoring: Rationale behind the 722 protocol.Journal of clinical hypertension (Greenwich, Conn.) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 7 countries.

Hung-Ju LinCardiovascular, Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Heng-Yu PanDepartment of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan.
Chen-Huan ChenDepartment of Medicine, National Yang Ming Chiao Tung University College of Medicine, Taipei, Taiwan.
Hao-Min ChengInstitute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Yook-Chin ChiaDepartment of Medical Sciences, School of Medical and Life Sciences, Sunway University, Selangor Darul Ehsan, Bandar Sunway, Malaysia.
Guru Prasad SogunuruFortis Hospitals, Chennai, Tamil Nadu, India.
Jam Chin TayDepartment of General Medicine, Tan Tock Seng Hospital, Singapore City, Singapore.
Yuda TuranaDepartment of Neurology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Narsingh VermaAsia Pacific Society of Hypertension, Department of Physiology, King George's Medical University, Lucknow, India.
Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Tzung-Dau WangCardiovascular Center and Divisions of Cardiology and Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
National Taiwan University Hospital · TWAtma Jaya Catholic University of Indonesia · IDCollege of Medical Sciences · NPJichi Medical University · JPKing George's Medical University · INNational Taiwan University · TWNational Yang Ming Chiao Tung University · TWSunway University · MYTaipei Veterans General Hospital · TWTan Tock Seng Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Home blood pressure (HBP) has been recognized as a prognostic predictor for cardiovascular events, and integrated into the diagnosis and management of hypertension. With increasing accessibility of oscillometric blood pressure devices, HBP monitoring is easy to perform, more likely to obtain reliable estimation of blood pressures, and feasible to document long-term blood pressure variations, compared to office and ambulatory blood pressures. To obtain reliable HBP estimates, a standardized HBP monitoring protocol is essential. A consensus regarding the optimal duration and frequency of HBP monitoring is yet to be established. Based on the current evidence, the "722" protocol, which stands for two measurements on one occasion, two occasions a day (morning and evening), and over a consecutive of 7 days, is most commonly used in clinical studies and recommended in relevant guidelines and consensus documents. HBP monitoring based on the "722" protocol fulfills the minimal requirement of blood pressure measurements to achieve agreement of blood pressure classifications defined by office blood pressures and to predict cardiovascular risks. In the Taiwan HBP consensus, the frequency of repeating the "722" protocol of HBP monitoring according to different scenarios of hypertension management, from every 2 weeks to 3 months, is recommended. It is reasonable to conclude that the "722" protocol for HBP monitoring is clinically justified and can serve as a basis for standardized HBP monitoring.

Indexed as

Blood Pressure Monitoring, AmbulatoryHypertensionBlood PressureBlood Pressure DeterminationHumansPrognosis

Identifiers

PMID36196472
PMCPMC9532917
OpenAlexW4301431280

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.